HPV Testing and Pap Test Market size is projected to experience significant growth from 2019 to 2025. Increasing incidents of cervical cancer globally will drive the HPV and Pap test market during the analysis period. According to WHO, cervical cancer is fourth most frequent cancer in women and in 2018, around 5,70,000 new cases were diagnosed. Thus, increasing cases of cervical cancer has boosted the demand for HPV testing and Pap testing. Also, according to the same source, over 90% of deaths due to cervical cancer have been encountered in middle- and low-income countries. Government in underdeveloped and emerging economies have reduced the prices of HPV and Pap tests that has helped in minimizing mortality rates thereby, positively impacting the industry growth.
Growing awareness regarding early detection of cervical cancer among women in developing economies will propel the HPV testing and Pap tests market growth. Government and regional authorities implement certain initiatives that drives the demand for cancer detections tests and kits. For instance, CDC created National Breast and Cervical cancer early detection program that provides free or low-cost screening process for women. Also, in May 2018, WHO framed laws to elimination of cervical cancer. Hence, increasing government support to create awareness about cervical cancer will foster industry growth. Although, the industry witnesses several growth opportunities, lack of trained professionals in underdeveloped countries for carrying out the tests will hamper the industry growth to come extent.
Request sample copy of this report @ https://www.gminsights.com/request-sample/detail/3174
Pap test segment will experience lucrative growth during analysis timeframe. Recently developed Pap test kits are relatively more accurate and can diagnose cervical cancer efficiently in earlier stages. For instance, Hologic has developed ThinPrep Pap test systems and Aptima HPV assays. These tests maximize lab efficiency and also provide accuracy in detection. Therefore, adoption of technologically advanced test kits will trigger the segmental growth.
Cervical cancer segment held considerable share and will have similar growth trends during analysis timeframe. Increasing incidences of cervical cancer cases in developing as well as developed countries will augment HPV and Pap test market. HPV test is the most effective test to detect human Papilloma virus and hence, it is widely used in detecting cervical cancer so that it can be treated if diagnosed in earlier stages. Moreover, women in developed countries routinely undergo HPV detection tests that helps to reduce the risk of acquiring cervical cancer. Aforementioned factors are expected to stimulate the segmental growth.
Make Inquiry about this report @ https://www.gminsights.com/inquiry-before-buying/3174
Hospitals segment accounted for significant revenue share in 2018. Due to an increase in healthcare expenditures globally, public as well as private hospitals are well equipped with assays and test kits to diagnose cervical and vaginal cancer. Thus, increasing patient inflow in hospitals for diagnosis of cancer will spur the segmental growth. Moreover, availability of advanced equipment, trained staff coupled with growing demand and comparatively low-cost diagnostic tests will further propel business growth.
U.S. dominates North America HPV testing and Pap test market owing to increasing prevalence of cervical cancer in the country. According to American Cancer Society, around 13,170 new cases of cervical cancer will be diagnosed in 2019 thus, rising patient pool will drive the country market growth. Additionally, favorable trade policies in the U.S. lowers entry barrier for new players willing to capture considerable market share in the HPV testing and Pap test market. Also, awareness level regarding early detection of cervical and vaginal cancer is high in the U.S. that further propels industry growth.
Eminent industry players in HPV testing and Pap test market are Qiagen, Abbott Laboratories, Becton Dickinson & Company, Hologic, Quest Diagnostics, Femasys, Roche Diagnostics, Arbor Vita Corporation, Onco Health Corporation, Seegene. Industry players focus inorganic strategies such as mergers and acquisitions to expand existing product portfolio. Also, receiving approvals from regulatory authorities for new product launch will render company with competitive advantage. For instance, in February 2018, Becton Dickinson company received FDA approval for its HPV test kit. Therefore, receiving approvals for new products will enhance company’s sales and foster its revenue generation.
- Abbott Laboratories
- Becton Dickinson & Company
- Quest Diagnostics
- Roche Diagnostics
- Arbor Vita Corporation
- Onco Health Corporation
Browse more reports: –